The membranes' role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation

Antiviral Research

Volumn 71, Issue 1, 2006, Pages 69-72

  Veiga, Ana Salomé ^a   Castanho, Miguel A R B ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

Fluorescence; HIV 1; MAb 2F5; Membrane

Indexed keywords

MONOCLONAL ANTIBODY 2F5; NEUTRALIZING ANTIBODY;

ARTICLE; CATALYSIS; CELL MEMBRANE; FLUORESCENCE; HUMAN IMMUNODEFICIENCY VIRUS 1; MEMBRANE MODEL; MEMBRANE VESICLE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VIRUS ENVELOPE;

AMINO ACIDS, AROMATIC; ANTIBODIES, MONOCLONAL; EPITOPES; FLUORESCENT DYES; FLUOROMETRY; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOTHERAPY; MEMBRANES; PHOSPHATIDYLCHOLINES; PYRIDINIUM COMPOUNDS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33745186702     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.02.002     Document Type: Article

References (31)

1. Aloia R.C., Tian H., and Jensen F.C. Lipid composition and fluidity of the human immunodeficiency virus envelope and host cell plasma membranes. Proc. Natl. Acad. Sci. USA 90 (1993) 5181-5185
2. Barbato G., Bianchi E., Ingallinella P., Hurni W.H., Miller M.D., Ciliberto G., Cortese R., Bazzo R., Shiver J.W., and Pessi A. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. J. Mol. Biol. 330 (2003) 1101-1115
3. Campbell S.M., Crowe S.M., and Mak J. Virion-associated cholesterol is critical for the maintenance of HIV-1 structure and infectivity. AIDS 16 (2002) 2253-2261
4. Castanho M.A.R.B., and Fernandes M.X. Lipid membrane-induced optimization for ligand-receptor docking: recent tools and insights for the 'membrane catalysis' model. Eur. Biophys. J. 35 (2006) 92-103
5. Chan D.C., and Kim P.S. HIV entry and its inhibition. Cell 93 (1998) 681-684
6. Cladera J., Martin I., and O'Shea P. The fusion domain of HIV gp41 interacts specifically with heparan sulfate on the T-lymphocyte cell surface. EMBO J. 20 (2001) 19-26
7. Cladera J., and O'Shea P. Intramembrane molecular dipoles affect the membrane insertion and folding of a model amphiphilic peptide. Biophys. J. 74 (1998) 2434-2442
8. Cooley L.A., and Lewin S.R. HIV-1 cell entry and advances in viral entry inhibitor therapy. J. Clin. Virol. 26 (2003) 121-132
9. 1 and alcohol dehydrogenase fluorescence quenching by acrylamide. J. Chem. Educ. 70 (1993) 425-428
10. de Rosny E., Vassell R., Jiang S., Kunert R., and Weiss C.D. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes. J. Virol. 78 (2004) 2627-2631
11. D'Souza M.P., Livnat D., Bradac J.A., Bridges S.H., the AIDS clinical trials group antibody selection working group, and and collaborating investigators. Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. J. Infect. Dis. 175 (1997) 1056-1062
12. Eckert D.M., and Kim P.S. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70 (2001) 777-810
13. Follis K.E., Larson S.J., Lu M., and Nunberg J.H. Genetic evidence that interhelical packing interactions in the gp41 core are critical for transition of the human immunodeficiency virus type 1 envelope glycoprotein to the fusion-active state. J. Virol. 76 (2002) 7356-7362
14. Gorny M.K., and Zolla-Pazner S. Recognition by human monoclonal antibodies of free and complexed peptides representing the prefusogenic and fusogenic forms of human immunodeficiency virus type 1 gp41. J. Virol. 74 (2000) 6186-6192
15. Grundner C., Mirzabekov T., Sodroski J., and Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76 (2002) 3511-3521
16. Killian J.A., and von Heijne G. How proteins adapt to a membrane-water interface. Trends Biochem. Sci. 25 (2000) 429-434
17. LaBranche C.C., Galasso G., Moore J.P., Bolognesi D.P., Hirsch M.S., and Hammer S.M. HIV fusion and its inhibition. Antiviral Res. 50 (2001) 95-115
18. Lakowicz J.R. Principles of Fluorescence Spectroscopy. 2nd ed. (1999), Kluwer Academic/Plenum Publishers, New York
19. Mayer L.D., Hopes M.J., and Cullis P.R. Vesicles of variable sizes produced by a rapid extrusion procedure. Biochim. Biophys. Acta 858 (1986) 161-168
20. Muster T., Steindl F., Purtscher M., Trkola A., Klima A., Himmler G., Ruker F., and Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67 (1993) 6642-6647
21. Ofek G., Tang M., Sambor A., Katinger H., Mascola J.R., Wyatt R., and Kwong P.D. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78 (2004) 10724-10737
22. O'Shea P. Intermolecular interactions with/within cell membranes and the trinity of membrane potentials: kinetics and imaging. Biochem. Soc. Trans. 31 (2003) 990-996
23. Parker C.E., Deterding L.J., Hager-Braun C., Binley J.M., Schülke N., Katinger H., Moore J.P., and Tomer K.B. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J. Virol. 75 (2001) 10906-10911
24. Raulin J. Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog. Lipid Res. 41 (2002) 27-65
25. Sargent D.F., and Schwyzer R. Membrane lipid phase as catalyst for peptide-receptor interactions. Proc. Natl. Acad. Sci. USA 83 (1986) 5774-5778
26. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., and Moore J.P. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 (1995) 6609-6617
27. Veiga A.S., Santos N.C., Loura L.M.S., Fedorov A., and Castanho M.A.R.B. HIV fusion inhibitor peptide T-1249 is able to insert or adsorb to lipidic bilayers. Putative correlation with improved efficiency. J. Am. Chem. Soc. 126 (2004) 14758-14763
28. Veiga S., Yuan Y., Li X., Santos N.C., Liu G., and Castanho M.A.R.B. Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions. Biochim. Biophys. Acta 1760 (2006) 55-61
29. White S.H., and Wimley W.C. Hydrophobic interactions of peptides with membrane interfaces. Biochim. Biophys. Acta 1376 (1998) 339-352
30. Wyatt R., and Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280 (1998) 1884-1888
31. Zwick M.B., Labrijn A.F., Wang M., Spenlehauer C., Saphire E.O., Binley J.M., Moore J.P., Stiegler G., Katinger H., Burton D.R., and Parren P.W.H.I. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75 (2001) 10892-10905